OCULAR THERAPEUTIX, INC (OCUL) - Dilution Analysis

10-Q filing | 224.1M shares outstanding

10-Q filing | 172.6M shares outstanding

10-Q filing | 169.4M shares outstanding

10-K filing | 158.3M shares outstanding

10-Q filing | 115.0M shares outstanding

10-Q filing | 115.0M shares outstanding

10-Q filing | 154.7M shares outstanding

10-K filing | 79.8M shares outstanding

8-K filing: The company conducted an unregistered offering and sale of Shares and Pre-Funded Warrants pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act, with the Investors representing they are institutional "accredited investors" or "qualified institutional buyers" acquiring the securities for investment purposes only.

8-K filing: Ocular Therapeutix, Inc. announced an underwritten public offering of 30,800,000 shares of common stock at a public offering price of $3.25 per share. ($93.6M proceeds)

10-Q filing | 79.4M shares outstanding

S-3 filing: Ocular Therapeutix, Inc. files an S-3 registration statement for the offering of debt securities, common stock, preferred stock, depositary shares, warrants, and units with an aggregate offering price of up to $300,000,000.

10-Q filing | 78.0M shares outstanding

10-Q filing | 77.4M shares outstanding

10-K filing | 76.9M shares outstanding

10-Q filing | 77.0M shares outstanding

10-Q filing | 76.8M shares outstanding

10-Q filing | 76.7M shares outstanding

10-K filing | 76.4M shares outstanding

POS AM filing: Oculus VisionTech, Inc. may offer and sell securities from time to time in one or more offerings of up to $300,000,000 in aggregate offering price.

10-Q filing | 76.6M shares outstanding

10-Q filing | 76.3M shares outstanding

8-K filing: Termination of Open Market Sale Agreement with Jefferies where 10,321,840 shares of common stock were sold for gross proceeds of $48.7 million. ($48.7M proceeds)

10-Q filing | 76.1M shares outstanding

10-K filing | 76.0M shares outstanding

8-K filing: Ocular Therapeutix, Inc. completed an underwritten public offering of 3,725,000 shares of common stock at a public offering price of $21.50 per share, with the underwriters having an option to purchase up to an additional 558,750 shares. ($74.8M proceeds)

10-Q filing | 50.3M shares outstanding

8-K filing: Ocular Therapeutix, Inc. completed a public offering of 7,180,000 shares of common stock, with an additional 1,077,000 shares purchased through the underwriter's option, at a public offering price of $9.75 per share, resulting in net proceeds of approximately $75.2 million. ($0.0M proceeds)

10-Q filing | 50.3M shares outstanding

8-K filing: Ocular Therapeutix, Inc. completed a public offering of 9,409,091 shares of common stock at a price of $5.50 per share, resulting in net proceeds of approximately $48.2 million after deducting underwriting discounts, commissions, and estimated offering expenses. ($51.75M proceeds)

10-Q filing | 53.4M shares outstanding

10-K filing | 52.6M shares outstanding